InMed Pharmaceuticals Inc. completed a one-for-ten reverse stock consolidation and legally changed its name to Mentari Therapeutics, Inc., effective November 4, 2026. The company also reported that shareholders approved key proposals at its annual general meeting, including the Nasdaq Share Issuance Proposal for an upcoming merger with Mentari Therapeutics, a Delaware corporation, which will result in a change of control and redomestication to Nevada. Following the consolidation, outstanding shares decreased from approximately 5.49 million to roughly 549,374. The company expects to issue one contingent value right for each post-consolidated share held by shareholders of record as of November 5, 2026. InMed Pharmaceuticals Inc. is a pharmaceutical company focused on developing proprietary small molecule drug candidates targeting the CB1/CB2 receptors.
